Patient-reported outcomes in light of supportive medications in treatment-naïve lung cancer patients.
Johnny Hoang(University of Houston), Meghana V. Trivedi(University of Houston), Tito R. Mendoza(The University of Texas MD Anderson Cancer Center), Navneet Upadhyay(Eli Lilly (United States)), Dozie Dike(University of Houston), Hua Chen(Shanghai Jiao Tong University), Jae-Kyu Lee(University of Houston), Charles S. Cleeland(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
|JNCI Journal of the National Cancer Institute|2014|1.1k
Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
|JAMA Oncology|2015|1k
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273
Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize
|Cancer Research|2018|221